Capricor Therapeutics, Inc. logo CAPR - Capricor Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $50.00 DETAILS
HIGH: $62.00
LOW: $38.00
MEDIAN: $50.00
CONSENSUS: $50.00
UPSIDE: 122.22%

Stock News

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company's HOPE-3 Phase 3 trial.

Jun 26, 2026 05:05 AM • globenewswire.com
Caprock Announces Closing of Private Placement

Caprock Announces Closing of Private Placement

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.

Jun 19, 2026 01:47 PM • newsfilecorp.com
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.

Jun 17, 2026 12:32 PM • newsfilecorp.com
Caprock Announces Proposed Private Placement

Caprock Announces Proposed Private Placement

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering.

Jun 12, 2026 02:02 PM • newsfilecorp.com
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m.

Jun 12, 2026 01:40 PM • newsfilecorp.com
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints GMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected Cash balance of approximately $279 million expected to support operations into Q4 2027 Eligible for a Priority Review Voucher upon approval; PRV is transferable and monetizable, offering potential non-dilutive capital Conference call and webcast today at 4:30 p.m.

May 12, 2026 12:05 PM • globenewswire.com
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026.

May 04, 2026 12:05 PM • globenewswire.com

Price Targets